Status:
RECRUITING
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
Lead Sponsor:
Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions:
Moderate-to-severe Atopic Dermatitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.
Eligibility Criteria
Inclusion
- The subjects have voluntarily signed the informed consent form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study.
- At the time of signing the informed consent, the subjects are ≥ 18 years old and ≤ 75 years old, male or female.
- Have atopic dermatitis at screening.
Exclusion
- Hypersensitivity to the study drug or any ingredient in the study drug.
- Have other active skin disease or skin complications due to other conditions that may affect the evaluation of Atopic Dermatitis (AD).
- Has malignancy or has a history of malignancy.
- Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial.
- Females who are pregnant or lactating.
Key Trial Info
Start Date :
November 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT07211542
Start Date
November 7 2025
End Date
February 1 2027
Last Update
December 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510091